Drug Trial Radar · NCT06183736
CVL237 Tablets in the Treatment of Advanced Solid Tumors With PTEN Deficiency
Last checked: Nov 19, 2026Latest source record: Dec 27, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
98
Planned (sponsor's estimate)
Start
Dec 20, 2023
Primary completion
Jun 30, 2025
Study completion Jun 30, 2027
Sponsor
- Lead sponsor
- Convalife (Shanghai) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 27, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a single-arm, open-label, multicenter, phase II study of CVL237 tablets in the treatment of advanced solid tumors with PTEN deficiency. It is planned to enroll patients with PTEN deficiency advanced solid tumors of different tumor types (PTEN deficiency gastric cancer, prostate cancer, endometrial cancer, colorectal cancer, lung cancer, breast cancer and melanoma etc.) to evaluate the preliminary efficacy, safety and pharmacokinetic profile of CVL237 tablets in patients with PTEN deficiency advanced solid tumors of different tumor types.
Conditions
- Advanced Solid Tumors
Interventions
CVL237 tabletsDrug
CVL237 tablets, 200 mg, taken with food once daily for 28 consecutive days as a treatment cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rate (ORR) in patients with PTEN deficiency as assessed according to RECIST v1.1Time frame: Throughout the study for approximately 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Li Ning
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.